Background {#Sec1}
==========

Electronic cigarettes (e-cigarettes), battery-operated devices that vaporize nicotine and produce an inhaled aerosol, have burgeoned into a billion-dollar industry in the United States (U.S.) with over \$10 billion (US dollars) in revenues by 2017 \[[@CR1]\]. Contributing to the increase in revenue has been growing awareness and use of e-cigarettes by the general population \[[@CR1], [@CR2]\]. As e-cigarette use continues to grow, more research on the health effects and patterns of e-cigarette use is needed to inform policies. Although e-cigarettes are marketed as being less harmful to health than regular cigarettes \[[@CR3]\], and have shown potential to satisfy nicotine addiction while delivering fewer toxicants \[[@CR4]\], controversy exists about the promotion, safety, and use of e-cigarettes \[[@CR5], [@CR6]\]. Some previous longitudinal studies indicate that there is a benefit for reduction or cessation of tobacco cigarettes \[[@CR7]--[@CR12]\], while others point to no or little benefit \[[@CR13]--[@CR16]\]. Studies have also shown that e-cigarettes could deliver potentially greater amounts of nicotine than tobacco cigarettes \[[@CR15]--[@CR18]\] and lead to renormalization of smoking \[[@CR19]\].

Due to the high urgency to quit cigarette smoking during pregnancy and the potential efficacy of e-cigarettes as a smoking cessation device \[[@CR7]--[@CR12]\], pregnant women may be particularly interested in using e-cigarettes to assist with quitting or reducing cigarette smoking. Smoking during pregnancy has been shown to cause pregnancy complications and adverse fetal outcomes, such as preterm-related deaths, sudden infant deaths, and low birth-weights \[[@CR20]\]. It is estimated that 8.4--10.2% of pregnant women smoke during their pregnancy in the U.S. \[[@CR21]\]. Rates are also higher among women who have less than a high school education, Medicaid insurance, are of White or Native American ancestry, and are between the ages of 20--24 years old \[[@CR21], [@CR22]\]. Given the lack of conclusive evidence regarding the efficacy of e-cigarettes for smoking cessation and concerns about their harms, a better understanding of e-cigarette use by pregnant smokers is necessary.

There is a dearth of research conducted to date focusing on the effects of e-cigarette use among pregnant women and few estimates exist on the prevalence of e-cigarette use among pregnant women. A recent systematic review found that the prevalence of e-cigarette use during pregnancy ranges from 0.6 to 15% \[[@CR23]\]. A 2017 study found that 8.54% (38/445) of pregnant women were dual users of tobacco cigarettes and e-cigarettes. The study also found that pregnant women view e-cigarettes as being safer than tobacco cigarettes \[[@CR24]\], even though e-cigarettes are not approved as a smoking cessation or reduction aid by the U.S. Food and Drug Administration \[[@CR24], [@CR25]\].

Given the potential link between nicotine exposure and adverse fetal and pregnancy outcomes \[[@CR26], [@CR27]\], understanding the motivations for and patterns of e-cigarette use among pregnant women is critical. The objectives of this study were to (i) identify trajectories of e-cigarette use, and (ii) examine the longitudinal association between e-cigarette use and smoking cessation among a U.S. national cohort of pregnant smokers.

Methods {#Sec2}
=======

Study population and design {#Sec3}
---------------------------

The sample for this analysis comes from the Quit4baby trial, a randomized controlled trial of text messaging for smoking cessation in pregnant women in the U.S. Recruitment for the study occurred between August, 2015 and February, 2016 \[[@CR28], [@CR29]\]. Participants (*N* = 508) were recruited from enrollees in Text4baby, the largest text messaging service for pregnant women and mothers in the United States. As such, all participants were receiving Text4baby text messages at the time of enrollment. Some participants were randomized to also receive Quit4baby \[[@CR29]\]. A detailed recruitment process is published elsewhere \[[@CR28]\]. This study was approved by the George Washington University Institutional Review Board.

To be eligible, participants had to have a cell phone for their personal use, be willing to receive text messages on their phone, be 14 years old or older, be pregnant at the time of enrollment and report having smoked at least one puff of cigarette in the past 2 weeks at the time of assessment \[[@CR29]\]. Per IRB protocol, participants were consented over the phone verbally, and for minors, parents were required to give consent and minors gave assent. The current analyses are limited to a sub-sample from this study who completed the 1-month follow-up survey and were still pregnant at the time of the follow-up (*n* = 428 participants including 4 minors; 13 were removed because they were no longer pregnant and 67 were removed because they did not complete the 1-month survey).

Measures {#Sec4}
--------

The primary cigarette smoking outcome for these analyses was self-reported 7-day point prevalence abstinence (PPA) at 1-month follow-up using the question, "Have you smoked a cigarette, even a puff, in the last 7 days?" (Additional file [1](#MOESM1){ref-type="media"}). Participants missing 7-day PPA were coded as smokers (*n* = 1). Secondary smoking outcomes included self-reported attempt to quit for longer than 1 day and changes in average cigarettes smoked per day (CPD) between 1-month and baseline. Changes in CPD was calculated by subtracting CPD at 1 month from CPD at baseline.

The main exposure variable of interest was use of e-cigarettes reported at baseline. E-cigarette use was assessed at both baseline and 1-month follow-up by asking "Have you used an e-cigarette, even once, in the past 7 days?" (Additional file [1](#MOESM1){ref-type="media"}). To track changes in e-cigarette use of the sample between baseline and 1-month follow-up, the sample was categorized into four different groups: "Continued non-users" (i.e. no e-cigarette use at both baseline and 1-month), "Continued users" (i.e. use of e-cigarette at both baseline and 1-month), "Stopped users" (i.e. use of e-cigarette at baseline, but stopped at 1-month) and "New users" (no e-cigarette usage at baseline, but initiated use of e-cigarette at 1-month).

Several variables potentially associated with smoking cessation and e-cigarette use were measured at baseline. Demographic characteristics included age, gestational age (in number of weeks), body mass index (BMI), race/ethnicity, employment, education, health insurance type, marital status, income, geographic region and intervention allocation (i.e. either Quit4baby + Text4baby; or Text4baby). Smoking variables included CPD at baseline, the Fagerstrom Test for Cigarette Dependence (FTCD) \[[@CR30], [@CR31]\] and motivation to quit smoking (1 = not at all, 7 = extremely). Additionally, we assessed the reasons for using e-cigarettes at baseline by listing out commonly reported reasons \[[@CR1], [@CR16], [@CR24]\] (e.g. safer for me than regular cigarettes, to help me quit, tastes good/does not smell).

Statistical analyses {#Sec5}
--------------------

Analyses for this study were conducted using SAS 9.4. Fisher Exact and Mann-Whitney U tests were used to compare groups of interest -- cigarette/e-cigarette dual-users and cigarette-only users, with respect to baseline demographic and smoking characteristics of the sample. To assess the association between the use of e-cigarettes at baseline and smoking cessation outcomes at 1-month, three logistic and linear regression models were constructed. Model 1 was an unadjusted bivariate logistic/linear regression. Model 2 was a multivariable logistic/linear regression that controlled for intervention allocation. Despite no differences in e-cigarette use observed between groups for intervention allocation, Model 2 was constructed because the intervention was shown to have positive smoking cessation outcomes \[[@CR29]\]. Model 3 was a multivariable logistic/linear regression that controlled for baseline characteristics (i.e. race/ethnicity) that were found to be significantly different between groups in addition to intervention allocation.

Results {#Sec6}
=======

Sample characteristics {#Sec7}
----------------------

Table [1](#Tab1){ref-type="table"} presents the overall baseline sample characteristics as well as characteristics for both e-cigarette/cigarette dual users and cigarette-only users. The sample (*n* = 428) was on average 26.39 years old (Standard Deviation (SD) = 5.80), 18.07 weeks pregnant (SD = 7.75) and had an average BMI of 27.73 (SD = 7.77). They were primarily non-Hispanic White (63.00%), unemployed (67.53%), with Medicaid or Medicare insurance (80.52%), with a high school degree or less (60.28%) and from the south (55.61%). At baseline, the sample smoked an average of 7.50 cigarettes per day (SD = 6.32), had an average FTCD score of 2.85 (SD = 2.28), and had a motivation to quit score of 6.04 out of 7 (SD = 1.31). There were no significant differences in demographic and smoking characteristics between participants lost to follow up and participants who completed the 1-month follow-up.Table 1Baseline characteristics of sampleCharacteristicsE-Cigarette & Cigarette dual user (*n* = 36)Cigarette user (*n* = 392)All (*n* = 428)Age, M (SD)26.86 (4.50)26.35 (5.91)26.39 (5.80)Gestational age, in weeks, M(SD)18.28 (7.48)18.05 (7.79)18.07 (7.75)Body mass index (BMI), M(SD)26.84 (5.45)27.81 (7.95)27.73 (7.77)Race/Ethnicity^a^ White30 (83.33)239 (61.13)269 (63.00) Black/African-American4 (11.11)100 (25.58)104 (24.36) Other2 (5.56)52 (13.30)54 (12.65)Education  \< 12 grade, no high school diploma6 (16.67)110 (28.06)116 (27.10) High school graduate, GED^b^ or equivalent12 (33.33)130 (33.16)142 (33.18) Some college16 (44.44)115 (29.34)131 (30.61) College degree2 (5.56)37 (9.44)39 (9.11)Employment status Working part/full-time13 (36.11)125 (32.13)138 (32.47) Not working23 (63.89)264 (67.87)287 (67.53)Annual household income  \< \$15,00022 (62.86)209 (54.43)231 (55.13) \$15,001--\$30,0008 (22.86)121 (31.51)129 (30.79)  \> \$30,0005 (14.29)54 (14.06)59 (14.08)Marital status Single, never married12 (33.33)156 (39.90)168 (39.34) Living with significant other9 (25.00)128 (32.74)137 (32.08) Married8 (22.22)80 (20.46)88 (20.61) Divorced/Separated/Widowed7 (19.44)27 (6.91)34 (7.96)Health insurance Medicaid/Medicare31 (86.11)312 (80.00)343 (80.52) Private, veterans or other3 (8.33)64 (16.41)67 (15.73) None2 (5.56)14 (3.59)16 (3.76)Cigarettes smoked per day, M(SD)8.44 (7.27)7.41 (6.23)7.50 (6.32)Fagerstrom test for cigarette dependence (0--10), M(SD)3.36 (2.54)2.80 (2.25)2.85 (2.28)Motivation to quit (1--7), M(SD)5.64 (1.53)6.08 (1.28)6.04 (1.31)Region West1 (2.78)27 (6.89)28 (6.54) Mid-west6 (16.67)94 (23.98)100 (23.36) Northeast2 (5.56)60 (15.31)62 (14.49) South27 (75.00)211 (53.83)238 (55.61)Allocated to intervention arm20 (55.56)188 (47.96)208 (48.60)^a^Significant difference (*p* ≤ 0.05) was observed between control and intervention group based on fisher exact test^b^*GED* General Educational Development testNote: Data are presentated as n(%) unless otherwise noted

At baseline, 8.41% of participants (*n* = 36) reported using e-cigarettes in the past 7 days and 17.29% (*n* = 74) reported using e-cigarettes in the past 30 days. At 1 month, 7.00% of participants (*n* = 30) reported using e-cigarette in the past 7 days and 11.92% (*n* = 51) reported using e-cigarettes in the past 30 days. No differences in demographic variables were observed between e-cigarette dual users (past 7-day) and cigarette-only users except race/ethnicity, where a greater percentage of dual users were non-Hispanic White (83.33% vs. 61.13%; *p* ≤ .05). There was no significant difference in the proportion of e-cigarette dual users between the 67 participants lost to follow up (12.9%) and participants who completed the 1-month follow-up (8.41%), *p* \> 0.05.

When asked about reasons for using e-cigarettes at baseline, 80.56% (*n* = 29) of women reported that they were using e-cigarettes to "help me quit", followed by "they are safer for me than regular cigarettes" (41.67% or 15/36), "e-cigarette tastes good and does not smell" (38.89% or 14/36) and "safer for my baby than regular cigarettes" (36.11% or 13/36). A small number also reported they were using e-cigarettes due to "cost" (13.89% or 5/36) or because "friends and family use them" (5.56% or 2/36).

E-cigarette use trajectory {#Sec8}
--------------------------

E-cigarette use between baseline and 1-month varied for some participants. A summary of e-cigarette use trajectory can be found in Table [2](#Tab2){ref-type="table"}. At baseline, 36 (8.41%) women used e-cigarettes in the past 7 days. At 1-month, 16 of these 36 women (44.44%) continued using e-cigarettes ("Continued") and 20 of these 36 women (55.56%) stopped using e-cigarettes ("Stopped"). Additionally, of 392 e-cigarette non-users at baseline, 14 (3.57%) started using e-cigarettes by 1-month ("New"). The majority of the sample (95.66% or 375/392) remained e-cigarette non-users at both time points ("Continued non-users"). Three women (0.70%) had missing e-cigarette use status at 1-month.Table 2Trajectories of e-cigarette use from baseline to 1-month follow-up1-month follow-up^a^Used e-cigarettesDid not use e-cigarettesBaselineUsed e-cigarettes36 (8.41%)Continued16 (44.44%)Stopped20 (55.56%)Did not use e-cigarettes392 (91.59%)New14 (3.57%)Continued non-users375 (95.66%)Total42830 (7.01%)395 (92.29%)^a^3 observations missing at 1-month follow-up

Among those four trajectory groups, "continued non-users" had the highest quit rate, with 26.4% (99/375) reporting 7-day PPA abstinence at 1-month, followed by "stopped users" (25.00% or 5/20), "continued users" (12.50% or 2/16) and "new users" (7.14% or 1/14).

Logistic and linear regression models {#Sec9}
-------------------------------------

Table [3](#Tab3){ref-type="table"} presents unadjusted and adjusted odds ratios for the association between e-cigarette use at baseline and smoking outcomes at 1-month follow-up. In the unadjusted model (Model 1), the odds of 7-day PPA were lower among participants who used e-cigarettes compared to those who did not use e-cigarettes, though differences were not significant (odds ratio \[OR\] = 0.70, 95% confidence interval \[CI\] = 0.30,1.64, *ns*). Additionally, no differences were observed between use of e-cigarette and attempt to quit for more than 1 day (OR = 1.09, 95% CI = 0.52, 2.28, *ns*) and differences in CPD (OR = − 0.029, 95% CI = − 1.75, 1.69, *ns*). In the multivariable models (Models 2 and 3), the association between e-cigarette usage and smoking outcomes were not statistically significant. A sensitivity analysis that included the 67 participants lost to follow up (coded as smokers) yielded similar results for the association between e-cigarette use at baseline and 7-day PPA at 1-month follow-up.Table 3Unadjusted and Adjusted Odds Ratios for the Association Between E-Cigarette Use and Smoking OutcomesOutcome variablesE-cigarette & cigarette dual user (*n* = 36)Cigarette user (*n* = 392)Model 1Model 2Model 3OR (95% CI)*p*-valueAOR (95% CI)*p*-valueAOR (95% CI)*p*-valueNot smoked in past 7 days^a^, *n*(%)7 (19.44)101 (25.77)0.70 (0.30, 1.64)0.410.64 (0.27, 1.53)0.310.79 (0.33, 1.92)0.61Quit for more than 1 day, *n*(%)25 (69.44)265 (67.60)1.09 (0.52, 2.28)0.821.04 (0.49, 2.20)0.921.20 (0.56, 2.55)0.64Difference in CPD, M(SD)−3.39 (5.54)−3.36 (4.97)−0.029 (−1.75, 1.69)0.970.04 (−1.67, 1.76)0.960.18 (−1.55, 1.91)0.84Note: Model 1 unadjusted, Model 2 adjusted for intervention allocation, Model 3 adjusted for intervention allocation and race/ethnicity; *OR* odds ratio, *AOR* adjusted odds ratio, *CPD* cigarettes per day^a^3 observations missing

Discussion {#Sec10}
==========

The current study is among the first to examine the use of e-cigarettes among pregnant smokers prospectively. In this national sample of pregnant smokers recruited in 2015 and 2016, 8.41% of pregnant cigarette smokers were found to also be concurrent e-cigarette users. E-cigarette users were found to be similar to non-users with the exception of being more likely to be of white ethnicity. More than half of those who used e-cigarettes at baseline had stopped using by 1-month follow-up. After adjusting for intervention assignment and demographic factors, no association was observed between e-cigarette use and cigarette smoking related outcomes.

The most prevalent reasons for using e-cigarette in our sample were to "help me quit smoking", followed by "e-cigarettes are safer for me compared to regular cigarettes." This is similar to findings from previous studies that examined perceptions of e-cigarette use among pregnant women \[[@CR1], [@CR24]\]. Given these perceptions despite unknown health implications of e-cigarettes, targeted research is needed to understand the causal relationship between exposure to e-cigarettes and pregnancy outcomes (i.e. birthweight, preterm delivery).

Similar to other U.S. based studies \[[@CR13], [@CR14], [@CR24]\], the majority of e-cigarette users in this study were non-Hispanic White (83%). In this study, the prevalence of e-cigarette dual use was 8.41%. Although our sample was limited to smokers enrolled in a smoking cessation text messaging program and as such, prevalence estimates may not be generalizable to all pregnant smokers, the prevalence of e-cigarette dual use in our sample mirrors estimates from a recent 2017 U.S.-based study, which found that 8.54% of pregnant women were e-cigarette dual users \[[@CR24]\]. Additionally, in 2017, 2.8% of U.S. adults were current e-cigarette users and among U.S. adults aged 18--24, a group that's most likely to be current e-cigarette users, the percentage was 5.2% \[[@CR32]\]. Findings from our study suggest that rates of e-cigarette use among pregnant women may exceed those of general tobacco cigarette users in the U.S., and that e-cigarette use may be initiated during pregnancy.

Although e-cigarettes could benefit adult smokers if used as a complete substitute for combustible tobacco smoking \[[@CR9]--[@CR12]\], evidence of the effectiveness of e-cigarettes as a cessation aid is still inconclusive \[[@CR33]\]. In this national sample of pregnant smokers, we found no evidence that e-cigarette use was associated with cigarette smoking related outcomes in the short term. However, recent randomized trials have shown that e-cigarettes are effective in aiding some adult smokers to quit or to reduce their cigarette consumption \[[@CR9]--[@CR12]\]. Further studies should consider recruiting a larger sample of pregnant women that use e-cigarettes and follow up for a longer period of time.

A strength of this study is the use of a large, national sample and therefore the findings can be generalized to pregnant women in the U.S. Our participants' demographic characteristics -- based on their predominantly White ethnicity, on public insurance (i.e. Medicaid), and having a household income of \$30,000 or less per year- were found to match those of previous national samples of pregnant smokers in the U.S. \[[@CR21]\].

Several limitations should be considered in this study. This study is a secondary analysis from an intervention study on quitting smoking. All participants were receiving health related text messages and therefore it is likely that the participants studied are more health-oriented than the general population of pregnant smokers. Additionally, as the number of e-cigarette users in our sample was relatively small, estimates may be unreliable. As with all self-reported measures, social desirability bias could be a limitation. Future studies may benefit from more targeted outreach of cigarette and e-cigarette dual users to examine the association between e-cigarette use and tobacco cigarette cessation. This study also did not collect information about the extent of e-cigarette use, frequency and duration of use, and the concentration of nicotine fluid in e-cigarettes. This information is critical to accurately classify participants as dual users as well as to have a comprehensive understanding of the safety and efficacy of e-cigarettes as a smoking cessation aid for this particular population. As a result, these findings should be interpreted with caution. Future research with appropriate measures is needed to further determine whether and how e-cigarettes can be an effective tobacco cigarette cessation or reduction aid for pregnant smokers.

Conclusions {#Sec11}
===========

These data are among the first to provide estimates for the prevalence of e-cigarette use during pregnancy, their trajectory of use and their association with smoking cessation for pregnant smokers. This secondary analysis of a national trial of pregnant smokers provides some indication that use of e-cigarettes to quit smoking may be common in pregnant smokers but found no association with improved smoking cessation outcomes. There is an urgent need to further examine the risk and benefits of e-cigarette use, especially during pregnancy.

Additional file
===============
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Additional file 1:Questionnaires. Baseline and 1-month follow-up questionnaires. (PDF 144 kb)
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